The goal of this observational study, drug-free, cross-sectional, single-center is todescribe the incidence and characteristics of the clinical course and any short- andmedium-term complications of patients with congenital heart disease of medical interest,and pediatric patients with cardiomyopathy, arrhythmic pathology or pulmonary arterialhypertension who have been affected by Sars-Cov-2 disease. The secondary objective of thestudy is to identify risk factors for the development of moderate-severe forms ofCOVID-19 disease in the study population.
This is an observational, drug-free, cross-sectional, single-centre study. All patients
followed at our centre and suffering from congenital heart disease treated with only
haemodynamic procedures haemodynamic procedures alone, as well as paediatric patients
suffering from cardiomyopathy, pulmonary hypertension or arrhythmic pathology whose
follow-up was still in progress at the time of the start of the pandemic (due to death or
for reasonsof the patient). The structural collection of data necessary for the
evaluation of targets will take place through the creation of a specific electronic
archive, in which census of all patients who have undergone follow-up at our centre since
01/01/2005 at the time of study approval and still in follow-up at the time of the start
of the pandemic.
Patients of all ages will be enrolled age, both paediatric and adult, followed at our
centre. It is estimated to include in the study approximately 5000 patients.
Inclusion Criteria:
- Patients of all ages with congenital heart disease undergoing hemodynamic procedures
at our center or in natural history
- Pediatric patients with cardiomyopathy, arrhythmic disease, or hypertension
pulmonary
- Obtaining informed consent
- Patients who have access to an e-mail address and a computer to complete the
questionnaire
Exclusion Criteria:
- Patients with congenital heart disease undergoing corrective or palliative surgical
treatment
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna 3181928, Italy
Simone Bonetti, MD, Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna